Literature DB >> 18317444

Primary and secondary disorders of lipid metabolism in pediatrics.

Peter O Kwiterovich1.   

Abstract

In the circulation, cholesterol and triglycerides are enveloped in apolipoproteins and phospholipids, and transported as complex particles called lipoproteins. Abnormal levels of lipoproteins occur in children either because of a genetic defect in lipid metabolism pathways (primary lipid disorders, e.g. familial hypercholesterolemia [FH]) or secondary to other diseases or conditions (e.g. insulin resistance) and can be clinically significant; for example, elevated low-density lipoprotein cholesterol levels are a major risk factor for future cardiovascular disease. Patients with primary lipid disorders in childhood such as FH can exhibit early atherosclerotic lesions in childhood. Other risk factors for cardiovascular disease, such as obesity and type 2 diabetes mellitus, are increasingly common in the pediatric population, and are often associated with dyslipidemia. Thus, pediatricians should be aware of how to screen, diagnose and treat dyslipidemia. The majority of lipid disorders in children can be managed with diet and lifestyle modification. Pharmacologic therapy (e.g. statins) may be added if target lipoprotein levels are not achieved. Clinicians may be guided in patient management by recent scientific statements from the American Heart Association; however, existing National Cholesterol Education Program treatment guidelines should be urgently updated to incorporate new evidence regarding atherosclerosis pathophysiology, obesity and the metabolic syndrome, emerging cardiovascular risk factors, and pharmacologic therapy in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317444

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  7 in total

1.  Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor.

Authors:  Siham El Aziz; Asma Chadli; Hassan El Ghomari; Ahmed Farouqi
Journal:  BMJ Case Rep       Date:  2012-05-23

Review 2.  Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease.

Authors:  Catherine J McNeal; Tala Dajani; Don Wilson; Andrea E Cassidy-Bushrow; Justin B Dickerson; Marcia Ory
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

Review 3.  Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Authors:  Anthony S Wierzbicki; Adie Viljoen
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

4.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

5.  Evaluation of cardiovascular risk in school children.

Authors:  Lutvo Sporisević; Vjekoslav Krzelj; Adnan Bajraktarević; Elmedina Jahić
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

6.  Maternal malnutrition and offspring sex determine juvenile obesity and metabolic disorders in a swine model of leptin resistance.

Authors:  Alicia Barbero; Susana Astiz; Clemente J Lopez-Bote; Maria L Perez-Solana; Miriam Ayuso; Isabel Garcia-Real; Antonio Gonzalez-Bulnes
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

7.  Biological Effect of Cynara cardunculus on Kidney Status of Hypercholesterolemic Rats.

Authors:  Abdullah Glil Alkushi
Journal:  Pharmacogn Mag       Date:  2017-10-11       Impact factor: 1.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.